Table 1.
Demographics and patients’ characteristics at baseline.
| Main indication for palivizumab | ||||
| Total | Congenital heart disease (CHD) | Preterm | 21trisomy | |
| N | 498 | 277 | 169 | 52 |
| Mean age (mo) [min-max] | 9.5 (0-24) | 11.6 (0-24) | 5.2 (1-23) | 12.5 (1-24) |
| Male | 267 (53.6%) | 130 (46.9%) | 100 (59.2%) | 37 (71.2%) |
| Female | 231 (46.4%) | 147 (53.1%) | 69 (40.8%) | 15 (28.8%) |
| Mean gestational age (wks) [min-max] | 35.6 (22-42) | 37.8 (24-42) | 31.1 (22-35) | 37.6 (36-40) |
| High flow humidified nasal cannula | 7 (1.4%) | 7 (2.5%) | 0 (0.0%) | 0 (0.0%) |
| Mechanical ventilation | 1 (0.2%) | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Presence of siblings | 304 (61.0%) | 149 (53.8%) | 113 (66.9%) | 42 (80.8%) |
| Attending preschool | 78 (15.7%) | 43 (15.5%) | 4 (2.4%) | 31 (59.6%) |
| With cyanosis originating from CHD | 115 (23.1%) | 115 (41.5%) | 2 (1.2%) | 0 (0.0%) |
| History of cardiac surgery | 179 (35.9%) | 179 (64.6%) | 0 (0.0%) | 0 (0.0%) |
| Scheduled for radical or Fontan operation | 33 (6.6%) | 33 (11.9%) | – | – |